There was a small clinical trial, by Mark Ratain, M.D., of the University of Chicago, that suggests that it is possible to take a lower dose of Zytiga (abiraterone) along with a low-fat breakfast and achieve a response similar to the one we would expect to see with a full dose on an empty stomach.
Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.
Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?
The standard dose of abiraterone acetate (Zytiga) is 1,000 mg. taken on an empty stomach, however, when just 250 mgs are taken with food, it seems that for many men this lower dosage has the same activity as Zytiga at 1,000 mg without food.
Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer.
The U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa. It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Statins have been in the prostate cancer news feeds for a long time. They are believed to potentiate the effects of the anti-hormonal agents used to treat metastatic castration-resistant prostate cancer (mCRPC). Different stages of prostate cancer as well as different treatment exposures might change the efficacy of statins.
The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.
Both Taxotere (docetaxel) and Zytiga (abiraterone) are approved for newly diagnosed men with very aggressive prostate cancer and who have not yet had any exposure to hormone therapy (ADT).
The two approvals lead us to the question, which of these treatment options would be best for you?
You have become castrate resistant and already have taken Provenge. Now, what treatment should be next? Currently, the two best options are either Zytiga (abiraterone) or Xtandi (enzalutamide). Which should come first?
One of the most puzzling questions faced by men with advanced prostate cancer has to do with deciding which drug to take first, Zytiga (abiraterone) or Xtandi (enzalutamide)?
The FDA has been asked to expand Zytiga's label to allow its use to treat men with earlier stages of metastatic prostate cancer.
On the horizon, a new Zytiga formulation. It's smaller and more active than the current Zytiga. It will be much easier to swallow.
Two game changing trials demonstrated that the early use of Zytiga along with hormone therapy (ADT) can provide a significant survival advantage for men with aggressive, hormone naive prostate cancer. The data is very clear for men with metastatic disease, but there remains some controversy if this holds up for men who are not metastatic.
Zytiga (abiraterone acetate) is now available in a new dosage and a new formulation. Zytiga can now be dispensed in tablets that are 500 mg instead of 250 mg and these new 500 mg tabs are film coated.